News Room

Plexus Ventures to Assist Jenarron Therapeutics to Out-license JA01 Lidocaine Rheo-gel for Pain Relief in Wound Repair

November 7, 2016

Philadelphia PA – Plexus Ventures, a global pharmaceutical consulting firm, announces its collaboration with Jenarron Therapeutics Ltd., ( a Belfast-based pharmaceutical company, to out-license JA01, their novel lidocaine rheo-gel product for pre-treatment and local anaesthesia of lacerations and similar wounds prior to suturing and wound repair.

Professor Paul McCarron, Managing Director of Jenarron Therapeutics, stated: “JA01 promises to be a significant benefit to patients requiring repair of lacerated and torn skin. This can be a painful and unpleasant experience, especially for children. JA01 is a lidocaine-containing, rheological hydrogel (rheo-gel) for pre-treatment of lacerations prior to suturing. JA01 is easily and painlessly applied, anaesthetizing the wound within 20 minutes. JA01 is completely removed as a solid, cleaning and debriding the wound ready for suturing. JA01 has successfully completed a pivotal Phase II open-label, randomised control study on pain relief sponsored by the Department of Health (NI) confirming non-inferiority to lidocaine infiltration with respect to pain experienced during suturing. We are extremely pleased to have engaged Plexus Ventures to assist Jenarron in its partnering activities.”

Dr. Roger Cox of Plexus Ventures, added: “We are delighted to work with Jenarron to find licensees to bring JA01 to market and take the pain out of wound repair. The administration of JA01 by nurses in triage will also increase the efficiency of laceration repair, one of the most common procedures in the Emergency Room setting. When approved, JA01 is expected to be the first topical product licensed for anaesthesia of lacerations and broken skin.”

About Jenarron Therapeutics

Jenarron Therapeutics is a privately held pharmaceutical development company located in Belfast, Northern Ireland. The largest shareholder is Innovation Ulster Ltd. (Ulster University). To learn more, visit

About Plexus Ventures

Now in its 26th year, Plexus Ventures provides strategic advice, business development and alliance management services to clients in the pharmaceutical, consumer healthcare and drug delivery industries worldwide. Plexus Ventures assists its clients in the areas of in-licensing, out-licensing, acquisitions, divestitures and strategic partnerships. With offices in Barcelona, Basel, Beijing, Indianapolis, London, Los Angeles, Milan, Oxford, Philadelphia, Sao Paulo and Tokyo, Plexus Ventures possesses the capabilities to effectively serve clients in North America, South America, Europe and Asia. Plexus Ventures is both well-known and well respected by leading research-based pharmaceutical companies worldwide.